Cargando…

Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis

OBJECTIVE: Pancreatic cancer is portrayed to become the second leading cause of cancer-related death within the next years. Potentially complicating surgical resection emphasizes the importance of an accurate TNM classification. In particular, the failure to detect features for non-resectability has...

Descripción completa

Detalles Bibliográficos
Autores principales: Gassert, Felix G., Ziegelmayer, Sebastian, Luitjens, Johanna, Gassert, Florian T., Tollens, Fabian, Rink, Johann, Makowski, Marcus R., Rübenthaler, Johannes, Froelich, Matthias F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921086/
https://www.ncbi.nlm.nih.gov/pubmed/34837511
http://dx.doi.org/10.1007/s00330-021-08356-0
_version_ 1784669260939788288
author Gassert, Felix G.
Ziegelmayer, Sebastian
Luitjens, Johanna
Gassert, Florian T.
Tollens, Fabian
Rink, Johann
Makowski, Marcus R.
Rübenthaler, Johannes
Froelich, Matthias F.
author_facet Gassert, Felix G.
Ziegelmayer, Sebastian
Luitjens, Johanna
Gassert, Florian T.
Tollens, Fabian
Rink, Johann
Makowski, Marcus R.
Rübenthaler, Johannes
Froelich, Matthias F.
author_sort Gassert, Felix G.
collection PubMed
description OBJECTIVE: Pancreatic cancer is portrayed to become the second leading cause of cancer-related death within the next years. Potentially complicating surgical resection emphasizes the importance of an accurate TNM classification. In particular, the failure to detect features for non-resectability has profound consequences on patient outcomes and economic costs due to incorrect indication for resection. In the detection of liver metastases, contrast-enhanced MRI showed high sensitivity and specificity; however, the cost-effectiveness compared to the standard of care imaging remains unclear. The aim of this study was to analyze whether additional MRI of the liver is a cost-effective approach compared to routinely acquired contrast-enhanced computed tomography (CE-CT) in the initial staging of pancreatic cancer. METHODS: A decision model based on Markov simulation was developed to estimate the quality-adjusted life-years (QALYs) and lifetime costs of the diagnostic modalities. Model input parameters were assessed based on evidence from recent literature. The willingness-to-pay (WTP) was set to $100,000/QALY. To evaluate model uncertainty, deterministic and probabilistic sensitivity analyses were performed. RESULTS: In the base-case analysis, the model yielded a total cost of $185,597 and an effectiveness of 2.347 QALYs for CE-MR/CT and $187,601 and 2.337 QALYs for CE-CT respectively. With a net monetary benefit (NMB) of $49,133, CE-MR/CT is shown to be dominant over CE-CT with a NMB of $46,117. Deterministic and probabilistic survival analysis showed model robustness for varying input parameters. CONCLUSION: Based on our results, combined CE-MR/CT can be regarded as a cost-effective imaging strategy for the staging of pancreatic cancer. KEY POINTS: • Additional MRI of the liver for initial staging of pancreatic cancer results in lower total costs and higher effectiveness. • The economic model showed high robustness for varying input parameters.
format Online
Article
Text
id pubmed-8921086
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-89210862022-03-17 Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis Gassert, Felix G. Ziegelmayer, Sebastian Luitjens, Johanna Gassert, Florian T. Tollens, Fabian Rink, Johann Makowski, Marcus R. Rübenthaler, Johannes Froelich, Matthias F. Eur Radiol Gastrointestinal OBJECTIVE: Pancreatic cancer is portrayed to become the second leading cause of cancer-related death within the next years. Potentially complicating surgical resection emphasizes the importance of an accurate TNM classification. In particular, the failure to detect features for non-resectability has profound consequences on patient outcomes and economic costs due to incorrect indication for resection. In the detection of liver metastases, contrast-enhanced MRI showed high sensitivity and specificity; however, the cost-effectiveness compared to the standard of care imaging remains unclear. The aim of this study was to analyze whether additional MRI of the liver is a cost-effective approach compared to routinely acquired contrast-enhanced computed tomography (CE-CT) in the initial staging of pancreatic cancer. METHODS: A decision model based on Markov simulation was developed to estimate the quality-adjusted life-years (QALYs) and lifetime costs of the diagnostic modalities. Model input parameters were assessed based on evidence from recent literature. The willingness-to-pay (WTP) was set to $100,000/QALY. To evaluate model uncertainty, deterministic and probabilistic sensitivity analyses were performed. RESULTS: In the base-case analysis, the model yielded a total cost of $185,597 and an effectiveness of 2.347 QALYs for CE-MR/CT and $187,601 and 2.337 QALYs for CE-CT respectively. With a net monetary benefit (NMB) of $49,133, CE-MR/CT is shown to be dominant over CE-CT with a NMB of $46,117. Deterministic and probabilistic survival analysis showed model robustness for varying input parameters. CONCLUSION: Based on our results, combined CE-MR/CT can be regarded as a cost-effective imaging strategy for the staging of pancreatic cancer. KEY POINTS: • Additional MRI of the liver for initial staging of pancreatic cancer results in lower total costs and higher effectiveness. • The economic model showed high robustness for varying input parameters. Springer Berlin Heidelberg 2021-11-27 2022 /pmc/articles/PMC8921086/ /pubmed/34837511 http://dx.doi.org/10.1007/s00330-021-08356-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Gastrointestinal
Gassert, Felix G.
Ziegelmayer, Sebastian
Luitjens, Johanna
Gassert, Florian T.
Tollens, Fabian
Rink, Johann
Makowski, Marcus R.
Rübenthaler, Johannes
Froelich, Matthias F.
Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
title Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
title_full Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
title_fullStr Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
title_full_unstemmed Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
title_short Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis
title_sort additional mri for initial m-staging in pancreatic cancer: a cost-effectiveness analysis
topic Gastrointestinal
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921086/
https://www.ncbi.nlm.nih.gov/pubmed/34837511
http://dx.doi.org/10.1007/s00330-021-08356-0
work_keys_str_mv AT gassertfelixg additionalmriforinitialmstaginginpancreaticcanceracosteffectivenessanalysis
AT ziegelmayersebastian additionalmriforinitialmstaginginpancreaticcanceracosteffectivenessanalysis
AT luitjensjohanna additionalmriforinitialmstaginginpancreaticcanceracosteffectivenessanalysis
AT gassertfloriant additionalmriforinitialmstaginginpancreaticcanceracosteffectivenessanalysis
AT tollensfabian additionalmriforinitialmstaginginpancreaticcanceracosteffectivenessanalysis
AT rinkjohann additionalmriforinitialmstaginginpancreaticcanceracosteffectivenessanalysis
AT makowskimarcusr additionalmriforinitialmstaginginpancreaticcanceracosteffectivenessanalysis
AT rubenthalerjohannes additionalmriforinitialmstaginginpancreaticcanceracosteffectivenessanalysis
AT froelichmatthiasf additionalmriforinitialmstaginginpancreaticcanceracosteffectivenessanalysis